Insightful conversations with leading experts in the field of health care, medical research, policy, and more from the New England Journal of Medicine (NEJM). Each episode examines the many complexities found at the junction of medicine and society.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"NEJM Interviews","authorlink":""},"src":"http:\/\/podcast.nejm.org\/interviews\/nejm_2011.365.issue-23.interview.mp3","thumb":{"src":"https:\/\/images.lystnfm.com\/tr:n-app_thumbnail_medium\/podcastsnw-202311\/037f7c-835a-d22b-3d3b9a_800.jpg"},"title":"NEJM Interview: Dr. Jerry Avorn on the evolving approach to drug safety in the United States","link":"javascript:;","id":"item-438751"},{"meta":{"author":"NEJM Interviews","authorlink":""},"src":"http:\/\/podcast.nejm.org\/interviews\/nejm_2011.365.issue-24.interview.mp3","thumb":{"src":"https:\/\/images.lystnfm.com\/tr:n-app_thumbnail_medium\/podcastsnw-202311\/037f7c-835a-d22b-3d3b9a_800.jpg"},"title":"NEJM Interview: Dr. Elliot Israel on the risks and benefits of long-acting beta agonists in the treatment of asthma and COPD.","link":"javascript:;","id":"item-438750"},{"meta":{"author":"NEJM Interviews","authorlink":""},"src":"http:\/\/podcast.nejm.org\/interviews\/nejm_2011.365.issue-25.interview.mp3","thumb":{"src":"https:\/\/images.lystnfm.com\/tr:n-app_thumbnail_medium\/podcastsnw-202311\/037f7c-835a-d22b-3d3b9a_800.jpg"},"title":"NEJM Interview: Dr. Robert Schwartz on the history of cancer research.","link":"javascript:;","id":"item-438749"}]
